Click to hear Dr Baglin's perspective on the role of the laboratory in treatment with new oral
anticoagulants Summary One of the key benefits of the direct oral anticoagulants (DOACs) is …

Background Direct oral anticoagulants (DOACs) are the treatment of choice for most patients
with atrial fibrillation and/or noncancer-associated venous thromboembolic disease …

This guidance document was prepared on behalf of the International Council for
Standardization in Haematology (ICSH) for providing haemostasis-related guidance …

The introduction of direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban,
apixaban, edoxaban, and betrixaban, provides safe and effective alternative to previous …

The actual incidence of neurologic dysfunction resulting from hemorrhagic complications
associated with neuraxial blockade is unknown. Although the incidence cited in the literature …

Introduction Direct oral anticoagulant (DOAC) intra-and inter-individual variability was
previously reported, but its magnitude is still considered negligible for patient management …

In 2018, the International Council for Standardization in Haematology (ICSH) published a
consensus document providing guidance for laboratories on measuring direct oral …

Direct oral anticoagulants (DOACs) have been licensed worldwide for several years for
various indications. Each year, 10–15% of patients on oral anticoagulants will undergo an …

Direct oral anticoagulants (DOAC s), including the direct thrombin inhibitor, dabigatran, and
the direct factor Xa (FX a) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for …

Oral vitamin K anticoagulation (warfarin, Coumadin, coumarin) has long been used for long-
term treatment and prophylaxis in a variety of clinical settings. Given the unpredictable …